

Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse

Patrick O McGowan^{1,2}, Aya Sasaki^{1,2}, Ana C D'Alessio³, Sergiy Dymov³, Benoit Labonté^{1,4}, Moshe Szyf^{2,3}, Gustavo Turecki^{1,4} & Michael J Meaney^{1,2,5}

Maternal care influences hypothalamic-pituitary-adrenal (HPA) function in the rat through epigenetic programming of glucocorticoid receptor expression. In humans, childhood abuse alters HPA stress responses and increases the risk of suicide. We examined epigenetic differences in a neuron-specific glucocorticoid receptor (*NR3C1*) promoter between postmortem hippocampus obtained from suicide victims with a history of childhood abuse and those from either suicide victims with no childhood abuse or controls. We found decreased levels of glucocorticoid receptor mRNA, as well as mRNA transcripts bearing the glucocorticoid receptor 1_F splice variant and increased cytosine methylation of an *NR3C1* promoter. Patch-methylated *NR3C1* promoter constructs that mimicked the methylation state in samples from abused suicide victims showed decreased NGFI-A transcription factor binding and NGFI-A-inducible gene transcription. These findings translate previous results from rat to humans and suggest a common effect of parental care on the epigenetic regulation of hippocampal glucocorticoid receptor expression.

There are maternal effects on the development of individual differences in behavioral and HPA stress responses in rodents and nonhuman primates^{1,2}. Maternal behavior alters the development of HPA responses to stress in the rat through tissue-specific effects on gene transcription^{3,4}, including forebrain glucocorticoid receptor expression, the activation of which inhibits HPA activity through negative-feedback inhibition⁵. Thus, selective knockdown of glucocorticoid receptor expression in the corticolimbic system in rodents is associated with increased HPA activity under both basal and stressful conditions^{6,7}. Conversely, glucocorticoid receptor overexpression is associated with a dampened HPA stress response⁸.

Familial function and childhood adversity are linked to altered HPA stress responses in humans, which are associated with an increased risk for multiple forms of psychopathology^{9–11}. There is evidence for decreased hippocampal glucocorticoid receptor expression in several psychopathological conditions associated with suicide, including schizophrenia and mood disorders^{12–14}. Suicide is also strongly associated with a history of childhood abuse and neglect, and this effect is independent of that associated with psychopathology^{15,16}. Thus, environmental events that associate with decreased hippocampal glucocorticoid receptor expression and increased HPA activity enhance the risk of suicide.

The effects of maternal care on hippocampal glucocorticoid receptor expression, and therefore HPA responses to stress, in the adult rodent are associated with an epigenetic modification of a neuron-specific

exon 1₇ glucocorticoid receptor (*Nr3c1*) promoter^{4,17}. We attempted to translate these findings to humans. We examined glucocorticoid receptor expression and *NR3C1* promoter methylation in hippocampal samples obtained from suicide victims and control subjects who died suddenly of unrelated causes. The focus of our examination was the *NR3C1* (also known as *GR1F*) promoter, the homolog of the exon 1₇ region in the rat¹⁸, which is highly expressed in human hippocampus¹⁹. Suicide victims were either positive or negative for history of childhood abuse (sexual contact, severe physical abuse and/or severe neglect), allowing for the separation of the effects associated with childhood abuse from those associated with suicide *per se*. Our controls were all negative for a history of childhood abuse.

RESULTS

Hippocampal glucocorticoid receptor expression

The human glucocorticoid receptor gene *NR3C1* covers a region of more than 80 kb in chromosome 5, containing eight coding exons (exons 2–9) and alternative 5' noncoding exon 1s^{19–21}. The 5' untranslated region (UTR) of exon 1 of the *NR3C1* gene determines the tissue-specific expression. The 5' UTR of *NR3C1* contains 11 exon 1 splice variants, all of which bear unique splice donor sites and share a common exon 2 splice acceptor site¹⁹. Exon 1_F of *NR3C1* is similar to the rat exon 1₇, which reveals a maternal effect on cytosine methylation and expression^{8,18,22}. Because individuals with severe forms of major depression show decreased glucocorticoid receptor

¹Douglas Mental Health University Institute, 6875 LaSalle Boulevard, Montreal, Quebec, H4H 1R3, Canada. ²Sackler Program for Epigenetics & Developmental Psychobiology, McGill University, 3655 Promenade Sir William Osler, Montreal, Quebec, H3G 1Y6, Canada. ³Department of Pharmacology and Therapeutics, McGill University, 3655 Promenade Sir William Osler, Montreal, Quebec, H3G 1Y6, Canada. ⁴McGill Group for Suicide Studies, 6875 LaSalle Boulevard, Douglas Mental Health University Institute, Montreal, Quebec, H4H 1R3, Canada. ⁵Singapore Institute for Clinical Sciences, Brenner Centre for Molecular Medicine, 30 Medical Drive, Singapore 117609. Correspondence should be addressed to M.J.M. (michael.meaney@mcgill.ca), G.T. (gustavo.turecki@mcgill.ca) or M.S. (moshe.szyf@mcgill.ca).

Received 18 August 2008; accepted 9 January 2009; published online 22 February 2009; doi:10.1038/nn.2270




Figure 1 Hippocampal glucocorticoid receptor expression. **(a,b)** Mean \pm s.e.m. expression levels of total glucocorticoid receptor (GR) mRNA **(a)** and glucocorticoid receptor 1_F (GR1_F) in 12 suicide victims with a history of childhood abuse, 12 nonabused suicide victims and 12 control subjects **(b)**. Outliers excluded from analysis included $n = 2$ control subjects, $n = 1$ suicide victims with a history of childhood abuse for glucocorticoid receptor 1_F and an additional $n = 1$ suicide victim with a history of childhood abuse, and $n = 3$ nonabused suicide victims for overall levels of glucocorticoid receptor. * indicates $P < 0.05$; n.s. indicates not statistically significant.

expression and increased HPA activity, we hypothesized that suicide victims would show decreased expression both of glucocorticoid receptor and glucocorticoid receptor 1_F compared with control subjects.

We examined the expression of total glucocorticoid receptor and glucocorticoid receptor 1_F using quantitative reverse transcription PCR (qRT-PCR) with RNA extracted from hippocampal tissue of suicide completers with ($n = 12$) and without ($n = 12$) a history of childhood abuse and from controls ($n = 12$). There was a significant effect on glucocorticoid receptor expression ($F = 3.17$, $P = 0.05$). *Post hoc* tests showed that expression of total glucocorticoid receptor mRNA was significantly reduced in suicide victims with a history of childhood abuse relative to nonabused suicide victims or controls ($P < 0.05$); there was no difference between nonabused suicide victims and controls ($P > 0.05$; **Fig. 1a**). There was also a significant effect on the expression of transcripts containing the exon 1_F *NR3C1* promoter ($F = 3.58$, $P < 0.05$). *Post hoc* tests revealed that glucocorticoid receptor 1_F expression was significantly lower in samples from suicide victims with a history of childhood abuse compared with suicide victims without childhood abuse or controls ($P < 0.05$). Similar to the findings with total glucocorticoid receptor mRNA expression, there was no difference between nonabused suicide victims and controls ($P > 0.05$; **Fig. 1b**).

We examined the relationship between glucocorticoid receptor expression and psychiatric diagnoses (**Table 1**). Mood disorders and substance abuse disorders are risk factors for suicide and have been linked to alterations of glucocorticoid receptor expression¹². There were no significant effects of psychopathology, even after controlling for childhood abuse status, on overall glucocorticoid receptor or glucocorticoid receptor 1_F expression ($P > 0.05$).

Genotyping and methylation analysis

Because alterations in glucocorticoid receptor 1_F activity could be derived from nucleotide sequence variation and/or epigenetic modifications, we sequenced the *NR3C1* promoter region from each subject. No sequence variation was seen among subjects and all of the sequences were identical to those published previously¹⁹. Moreover, for each subject, the genomic sequences targeted for binding by the

primers used for bisulfite mapping were identical to the published sequence¹⁹, thus eliminating potential primer bias between subjects in sodium bisulfite mapping.

The rat homolog of the exon 1_F *NR3C1* promoter, the exon 1_F region, is differentially methylated as a function of variations in maternal care^{4,17,22}. Cytosine methylation is a highly stable epigenetic mark that regulates gene expression via its effects on transcription factor binding^{23,24}. We used sodium bisulfite mapping²⁵ to examine the methylation status of individual CpG dinucleotides in the *NR3C1* promoter sequence extracted from the hippocampal tissue of the same subjects used for glucocorticoid receptor expression analysis. Sodium bisulfite mapping revealed a significant effect on the percentage of methylated clones (that is, the number of clones with at least one methylated CpG site divided by the total number of clones) between groups ($F = 3.47$, $P < 0.05$). *Post hoc* tests revealed a significant difference between suicide victims with a history of childhood abuse compared with nonabused suicide victims ($P = 0.05$) or controls ($P < 0.05$). There was no difference in the percentage of methylated clones between suicide victims without childhood abuse and controls ($P > 0.05$; **Fig. 2a**). Methylation was limited to specific sites, with no clone showing global methylation (**Fig. 2b**). There were no significant correlations between levels of exon 1_F methylation and age at death ($r = 0.15$, $P > 0.05$), brain pH ($r = 0.08$, $P > 0.05$) or postmortem interval (PMI, $r = 0.24$, $P > 0.05$; **Table 1**).

Patch methylation of the *NR3C1* promoter

DNA methylation of a limited number of sites in the exon 1_F *NR3C1* promoter was associated with decreased expression of the glucocorticoid receptor 1_F variant and of total glucocorticoid receptor mRNA in suicide victims with a history of childhood abuse. Defining a causal relation between the methylation status and transcriptional efficiency of the *NR3C1* promoter is therefore of great importance. We hypothesized that DNA methylation regulates the expression of the *NR3C1* promoter through alterations in transcription factor binding. The transcription factor NGFI-A regulates the expression of *Nr3c1* promoter in the rat, an effect that is inhibited by DNA methylation¹⁷. To our knowledge, the regulation of NGFI-A (also known as Zif268, EGR1, Krox-24 and ZENK) has not been studied in the human hippocampus, although there is evidence that its expression is downregulated in the prefrontal cortex in schizophrenia²⁶. The *NR3C1* promoter contains a number of canonical and noncanonical NGFI-A recognition elements (**Fig. 3a**). We wondered whether, as in the rat¹⁷, NGFI-A could regulate gene transcription through the *NR3C1* promoter and whether this effect might be influenced by the methylation status of the promoter. We used a transient transfection assay in human HEK293 cells to examine transcriptional activity of a *NR3C1* promoter ligated to a promoter-less firefly luciferase expression vector (pGEM-LUC, Promega; **Fig. 3a**) in the presence or absence of ectopic NGFI-A

Table 1 Demographic characteristics and psychiatric diagnoses

	Abused suicide	Nonabused suicide	Control
Male/female	12/0	12/0	12/0
Age (years)	34.2 \pm 10	33.8 \pm 11	35.8 \pm 12
PMI (h)	24.6 \pm 5.8	39.0 \pm 25.7	23.5 \pm 6.0
pH	6.3 \pm 0.24	6.5 \pm 0.29	6.5 \pm 0.22
Childhood abuse/neglect	12/0 (100%)	0/12 (0%)	0/12 (0%)
Mood disorder	8/12 (67%)	8/12 (67%)	0/12 (0%)
Alcohol/drug abuse disorder	9/12 (75%)	6/12 (50%)	5/12 (42%)

Data are presented as mean \pm s.d.




Figure 2 Methylation of the *NR3C1* promoter in the hippocampus. Twenty clones were sequenced for each subject for methylation mapping. **(a)** Mean \pm s.e.m. percentage of methylated clones for suicide victims with a history of childhood abuse ($n = 12$), suicide victims without a history of childhood abuse ($n = 12$) and controls ($n = 12$). The methylation percentage was calculated as the number of clones with at least one methylated CpG site divided by the total number of clones (* indicates $P \leq 0.05$; n.s. indicates not statistically significant). **(b)** Methylation of the *NR3C1* promoter region, showing the frequency of methylation observed at each CpG site for suicide victims with a history of childhood abuse, suicide victims with no history of childhood abuse and control subjects (* $P < 0.05$, ** $P < 0.001$, abused suicides versus controls; & $P < 0.05$, && $P < 0.001$, non-abused suicides versus controls; # $P < 0.05$, ## $P < 0.001$, abused suicides versus non-abused suicides; Bonferroni *post hoc* comparisons).

expression. The use of HEK293 cells allowed us to concurrently transfect a number of expression vectors with high efficiency. The absence of plasmid replication during the transient transfection assay precludes the loss of methylation via passive demethylation²⁷.

Luciferase expression was measured in the presence or absence of NGFI-A from the unmethylated *NR3C1* promoter plasmid compared with a methylated version. There was a significant effect of testing condition on the transcriptional activity of the exon 1_F *NR3C1* promoter ($F = 110.6$, $P < 0.0001$; **Fig. 3b**). *Post hoc* analysis revealed that the transcriptional activity of the unmethylated *NR3C1* promoter was significantly increased in the presence of the NGFI-A expression vector (*NR3C1* versus *NR3C1* + *EGR1*; $P < 0.0001$). Furthermore, methylation of the *NR3C1* promoter (the entire *NR3C1* construct was methylated *in vitro* and ligated to an unmethylated vector before transfection, *NR3C1-M*) reduced basal transcriptional activity of the *NR3C1* construct (*NR3C1* versus *NR3C1-M*, $P < 0.05$). Methylation of the *NR3C1* construct also blunted NGFI-A induction of transcription (*NR3C1* + *EGR1* versus *NR3C1-M* + *EGR1*, $P < 0.0001$).

These results indicate that methylation attenuates NGFI-A induction of gene expression through the *NR3C1* promoter. However, the decreased glucocorticoid receptor transcription observed in suicide victims with a history of childhood abuse was associated with differences in methylation levels occurring only at specific sites in the exon 1_F *NR3C1* promoter (**Fig. 2b**). An ANOVA examining the methylation of CpG dinucleotides across the exon 1_F *NR3C1* promoter revealed a significant effect of CpG site ($F = 13.86$, $P < 0.0001$), a significant

effect of group ($F = 17.12$, $P < 0.0001$) and a significant interaction between CpG site and group ($F = 13.44$, $P < 0.0001$). In NGFI-A recognition elements, methylation was observed at CpG sites 12, 13, 30, 31 and 32 (**Fig. 2b**). We therefore examined whether such selective, site-specific differences in methylation could alter transcriptional activation through the *NR3C1* promoter. Two deletion constructs of the *NR3C1* promoter were generated in which selected CpG dinucleotides were patch-methylated (**Fig. 3a**). CpG sites 12 and 13 were methylated in the 255-bp construct, whereas the 125-bp promoter construct was methylated at CpG sites 30, 31 and 32. Thus, each deletion construct included at least one known or putative NGFI-A binding site²⁸.

We used patch methylation to examine whether selective methylation at specific sites reduces NGFI-A binding to and transactivation through the exon 1_F *NR3C1* promoter. We found an effect of methylation status on transcription factor-induced gene expression from the *NR3C1* promoter (**Fig. 3c**). For the 125-bp construct, there was a significant effect of methylation status ($F = 57.6$, $P < 0.0001$) and




Figure 3 *In vitro* analysis of *NR3C1* promoter methylation. **(a)** The relative position of the *NR3C1* variant and the promoter sequence, showing the location of the CpG dinucleotides. The 255-bp (▼, solid underline) and 125-bp (▽, broken underline) deletion constructs are shown, along with specific CpG dinucleotides that were methylated in each deletion construct, as indicated by circles. Boxes represent known or putative canonical (solid-lined box) and noncanonical (broken-lined box) NGFI-A-binding sites, with the shaded area indicating the beginning of the exon. **(b,c)** Mean \pm s.e.m. levels of luciferase expression in HEK293 cells. Results are shown after the subtraction of expression of the promoter in the antisense orientation. **(b)** The full *NR3C1* promoter was either unmethylated (hGR) or completely patch methylated (hGR PatchM) and transfected in the presence or absence of NGFI-A. **(c)** The 255-bp and 125-bp *NR3C1* deletion construct were either unmethylated (255 bp or 125 bp) or methylated (255 bp M or 125 bp M), as shown in **a**, and transfected either in the presence or absence of NGFI-A.




Figure 4 NGFI-A association with exon 1_F *NR3C1* promoter constructs. (a–c) Quantification of *NR3C1* promoter immunoprecipitated with NGFI-A antibody and normalized to input DNA for the full human *NR3C1* promoter (a), the 255-bp deletion construct (b) and the 125-bp deletion construct (c), each of which was either unmethylated or methylated and transfected in the presence or absence of NGFI-A. Data are presented as means ± s.e.m.

NGFI-A treatment ($F = 6.3$, $P < 0.05$). As predicted, there was also a significant interaction between methylation status and the NGFI-A expression ($F = 48.7$, $P < 0.0001$). *Post hoc* analysis of the 125-bp *NR3C1* promoter construct revealed that the effect of NGFI-A on gene transcription was significantly ($P < 0.001$) greater in the presence of the unmethylated rather than the patch-methylated *NR3C1* promoter construct. The same pattern of results was observed for the 255-bp *NR3C1* promoter construct. Thus, for the 255-bp *NR3C1* promoter construct, there was a significant effect on transcriptional activity of methylation status ($F = 555.4$, $P < 0.0001$) and NGFI-A expression ($F = 387.3$, $P < 0.0001$). There was also a significant interaction between methylation status and the presence of NGFI-A ($F = 489.1$, $P < 0.0001$). *Post hoc* analysis revealed a significantly ($P < 0.001$) greater effect of NGFI-A on gene transcription in the presence of the unmethylated compared with the patch-methylated 255-bp *NR3C1* promoter construct.

NGFI-A association with the *NR3C1* promoter

Site-selective differences in methylation of CpG regions in promoters can alter gene transcription by affecting transcription factor binding²⁴. We carried out chromatin immunoprecipitation assays on samples that were obtained using the transfection model described above to examine the association of NGFI-A with the methylated and the nonmethylated *NR3C1* promoter constructs. The results revealed a significant effect of methylation status on NGFI-A association with the exon 1_F *NR3C1* promoter constructs transfected with *EGR1* ($F = 242.92$, $P < 0.0001$; **Fig. 4a**). *Post hoc* tests showed that, in comparison with the non-methylated construct, patch-methylation inhibited NGFI-A binding to the exon 1_F *NR3C1* promoter ($P < 0.005$; **Fig. 4a**). For the 125-bp promoter construct, there was a significant effect of methylation status ($F = 102.28$, $P < 0.001$) and NGFI-A treatment ($F = 209.99$, $P < 0.0005$) and a significant interaction between methylation status and the presence of NGFI-A ($F = 72.71$, $P < 0.005$). Similarly, for the 255-bp promoter construct, there was a significant effect of methylation status ($F = 95.18$, $P < 0.001$) and NGFI-A treatment ($F = 152.13$, $P < 0.0005$) and a significant interaction between methylation status and the presence of NGFI-A ($F = 67.75$, $P < 0.005$). *Post hoc* testing revealed that, in comparison with the nonmethylated version, patch-methylation inhibited NGFI-A binding to either the 255-bp or 125-bp promoter constructs ($P < 0.01$; **Fig. 4b,c**). These findings suggest that the site-selective methylation of the exon 1_F *NR3C1* promoter construct, mimicking the differences observed between samples obtained from suicide victims with a history of childhood abuse, reduces NGFI-A

binding and transcriptional activation through the exon 1_F *NR3C1* promoter.

DISCUSSION

Our findings indicate that hippocampal *NR3C1* gene expression is decreased in samples from suicide victims with a history of childhood abuse compared with controls (victims of sudden, accidental death with no history of abuse). In contrast, we found no differences in glucocorticoid receptor expression between suicide victims without a history of childhood abuse and controls. The pattern of results for hippocampal expression of the glucocorticoid receptor 1_F variant was identical to that of total glucocorticoid receptor expression. Our findings suggest that changes in glucocorticoid receptor expression are closely

associated with a developmental history of familial adversity, in this case a history of childhood abuse, than with suicide completion. These results are also similar to those of earlier reports in which childhood abuse was associated with an increase in pituitary adrenocorticotrophic hormone (ACTH) responses to stress among individuals with or without concurrent major depression¹¹. These findings are particularly relevant, as pituitary ACTH directly reflects central activation of the HPA stress response and hippocampal glucocorticoid receptor activation dampens HPA activity.

Our findings are also consistent with those from studies with rodent and nonhuman primates showing that persistent disruptions of mother-infant interactions are associated with increased hypothalamic corticotrophin-releasing hormone expression and increased HPA responses to stress^{1,2,29}. Variations in maternal care in the rat influence hippocampal glucocorticoid receptor expression, as well as methylation of the rat fetal calf serum *Nr3c1* promoter, the homolog of the human exon 1_F *NR3C1* promoter^{3,4,17,22}. Hippocampal samples from suicide victims showed increased methylation of the exon 1_F *NR3C1* promoter in comparison with samples from controls, but only in cases with a history of childhood abuse. Neither hippocampal glucocorticoid receptor expression nor the methylation status of the exon 1_F *NR3C1* promoter was altered in suicide victims with no history of abuse. These findings suggest that variation in the methylation status of the exon 1_F *NR3C1* promoter, similar to that for glucocorticoid receptor 1_F and total glucocorticoid receptor mRNA expression, associates with childhood adversity and not with suicide *per se*.

A recent study of human cord blood found a correlation between maternal mood and neonatal methylation status of glucocorticoid receptor 1_F³⁰. This study reported that increased site-specific methylation of an NGFI-A response element of glucocorticoid receptor 1_F is linked to an enhanced cortisol stress response in infants. Maternal mood disorders are associated with decreased maternal sensitivity and impaired mother-infant interactions³¹, as well as with an increased risk for depression in the offspring³². Decreased hippocampal glucocorticoid receptor expression associates with depression¹², and psychotic and severe forms of depression are commonly associated with increased HPA activity^{13,33}. Thus, our findings suggest that the transmission of vulnerability for depression from parent to offspring could occur, in part, through the epigenetic modification of genomic regions that are implicated in the regulation of stress responses.

One limitation of our design is the absence of samples from control subjects with a history of child abuse. Notably, child abuse predicts ACTH responses to stress¹¹. However, the best predictor of HPA

responses to stress is the interaction between a developmental history of child abuse and stress in adulthood. One interpretation for such findings is that childhood adversity might alter the development of systems that serve to regulate stress responses, such as hippocampal glucocorticoid receptor expression, and thus enhance the effect of stress in adulthood and vulnerability for mood disorders¹¹. Rodent models provide evidence for a direct effect of variations in forebrain glucocorticoid receptor expression and the behavioral characteristics of depression. Mice bearing a brain-specific glucocorticoid receptor knockdown show behavioral alterations that mimic some of the features of depression^{6,7,34}.

The data reported here are consistent with previous reports of alterations in cytosine methylation associated with psychopathology^{35–37}. We found increased site-specific methylation of the exon 1_F *NR3C1* promoter in suicide victims with a history of childhood abuse (Fig. 2). Our transfection studies with constructs that replicated the *in vivo* methylation profiles indicated that there was a relationship between cytosine methylation, transcription factor binding and gene expression. Variations in maternal care in the rat produce differential methylation of the exon 1₇ *Nr3c1* promoter, the rat homolog of the exon 1_F *NR3C1* promoter, which regulates hippocampal glucocorticoid receptor expression^{4,17,22} and HPA responses to stress^{3,4}. Increased CpG methylation of the *Nr3c1* promoter decreased NGFI-A binding and reduced hippocampal glucocorticoid receptor expression. Manipulations that reversed the differences in exon 1₇ methylation eliminated the maternal effect on NGFI-A binding, glucocorticoid receptor expression and HPA activity^{4,22}. Likewise, our *in vitro* data reveal that differential methylation of the human *NR3C1* promoter altered NGFI-A binding and NGFI-A-induced gene transcription. These findings suggest that selective differences in methylation status at certain sites affect transcription factor binding and gene expression.

Because cytosine methylation is a highly stable, the differences in CpG methylation are unlikely to be a consequence of events immediately preceding death or during the postmortem period. Therefore, changes in brain pH do not affect DNA methylation³⁸. The PMI did not differ between the groups and was uncorrelated with the methylation of the *NR3C1* promoter. The intermittent pattern of methylation and the fact that only a portion of the neuronal population was methylated in each subject is consistent with a model in which alterations in methylation occur at later stages in development, after the completion of embryogenesis and neuronal differentiation. Indeed, the maternal effect on the methylation status of the exon 1₇ *Nr3c1* promoter in the rat occurs during early postnatal life⁴.

There are precedents for the apparent developmental origins for the observed differences in DNA methylation and glucocorticoid receptor expression. Childhood abuse in humans is associated with altered hippocampal development³⁹, enhanced HPA activity^{9,11} and an increased risk for psychopathology^{15,16}. Similarly, children exposed to childhood adversity are more likely to engage in suicidal behavior^{40,41}. Variations in the parental care of children are linked with individual differences in HPA and sympathetic and central catecholamine responses to stress^{1,11,42,43}. Interventions that target parental care of high-risk children alter HPA activity⁴⁴. Thus, it is tempting to speculate that epigenetic processes might mediate the effects of the social environment during childhood on hippocampal gene expression and that stable epigenetic marks such as DNA methylation might then persist into adulthood and influence the vulnerability for psychopathology through effects on intermediate levels of function, such as HPA activity.

In summary, our data reveal increased site-specific methylation in the exon 1_F *NR3C1* promoter in suicide victims with a history of

childhood abuse and suggest that there is a relationship between cytosine methylation, transcription factor binding and gene expression. Our results are consistent with evidence from studies using psychological autopsy methods⁴⁰ and epidemiological longitudinal designs⁴⁵, which suggest that suicide has a developmental origin. We acknowledge that such conclusions are based on samples that differ along a wide range of experiential and potentially genetic dimensions. Our data certainly do not exclude alternative mechanisms of vulnerability. Indeed, the challenge for the future is to understand how epigenetic variation overlaying that occurring in nucleotide sequence might explain the developmental origins of vulnerability for chronic illness. Our data are merely consistent with observations from animal studies investigating epigenetic regulation of the *Nr3c1* gene and with the hypothesis that early life events can alter the epigenetic state of relevant genomic regions, the expression of which may contribute to individual differences in the risk for psychopathology.

METHODS

Postmortem sample preparation and subject characteristics. We used hippocampal samples from the Quebec Suicide Brain Bank (<http://www.douglasrecherche.qc.ca/suicide>), which included 12 suicide victims with a history of childhood abuse, 12 suicide victims with a negative history of childhood abuse (matched for psychiatric diagnoses) and 12 controls. All subjects were matched for PMI, gender and age (Table 1). Samples were processed as described previously⁴⁶ and consisted of hippocampus tissue from male suicides and control subjects of French-Canadian origin, dissected at 4 °C and stored at –80 °C. All subjects died suddenly with no medical or paramedical intervention. Suicides were determined by the Quebec Coroner's Office and the control subjects were individuals who had died suddenly from causes other than suicide. Homogenates of tissue samples were used for genomic DNA (DNeasy, Qiagen) and RNA (Trizol, Invitrogen) extraction. Possible confounds that were examined included PMI, brain pH and the age of the donor at death. Samples were processed and analyzed blindly with respect to demographic and diagnostic variables. Signed informed consent was obtained from next of kin.

Psychological autopsies. Psychiatric diagnoses were obtained using Structured Clinical Interviews for DSM-III-R I (ref. 47) adapted for psychological autopsies, which is a validated method for reconstructing psychiatric history by means of extensive proxy-based interviews, as described elsewhere⁴⁸. History of severe childhood sexual and/or physical abuse or severe neglect was determined by means of structured interviews using the Childhood Experience of Care and Abuse⁴⁹ questionnaire adapted for psychological autopsies⁴⁵.

Genotyping. Genomic DNA was extracted (DNeasy, Qiagen) according to the manufacturer's protocol. For PCR, we used a 5'-GGG TTC TGC TTT GCA ACT TC-3' sense primer and a 5'-CCT TTT TCC TGG GGA GTT G-3' antisense primer that were directed to the *NR3C1* promoter (Genbank accession number AY436590). Primers were selected that covered a 536-bp region that included the region for sodium bisulfite analyses. The resulting PCR products for each subject were sequenced bidirectionally using the forward and the reverse primer on an ABI 3100 genetic analyzer (Applied Biosystems) following the manufacturer's instructions. Genetic variation was assessed throughout the *NR3C1* promoter region used for bisulfite analysis by alignment of genomic DNA with the previously published *NR3C1* promoter sequence¹⁹ using freely available software (CLC Workbench, CLC bio).

Methylation mapping and expression analyses. Sodium bisulfite mapping was performed as previously described^{25,50} for 12 suicide victims with a history of childhood abuse, 12 suicide victims with a negative history of childhood abuse and 12 controls. Individual clones were extracted and sequenced (Cequation (8800), Beckman-Coulter). We obtained 20 clones per subject for sequencing from 2–3 independent PCR reactions.

RNA extraction was performed using Trizol (Invitrogen) and was followed by Dnase I treatment, and cDNA conversion was performed using oligo(dT) primers (Invitrogen) according to manufacturers instructions (Roche Molecular Biochemicals). The same subjects used for methylation analysis were studied

for expression analyses using quantitative RT-PCR. Outliers with expression values that differed more than 1.5 s.d. from the mean were excluded from analysis ($n = 2$ control subjects, $n = 1$ suicide victims with a history of childhood abuse for glucocorticoid receptor 1_F and $n = 2$ control subjects, $n = 2$ suicide victims with a history of childhood abuse and $n = 3$ nonabused suicide victims for overall levels of glucocorticoid receptor; see **Supplementary Methods** online).

HEK293 cell cultures and transient transfection assays. To prepare and transfect (and see ref. 17) the unmethylated and methylated plasmids, we subjected the exon 1_F *NR3C1* promoter to PCR amplification and cloned the resulting PCR product into a PCR2.1 plasmid (Original TA cloning kit, Invitrogen). The *NR3C1* promoter was then ligated into the PCR2.1 plasmid. For patch methylation, the glucocorticoid receptor 1_F plasmid was incubated (2 h, 37 °C) with SssI DNA methyltransferase (20 U, New England Biolabs) in a buffer containing S-adenosylmethionine, and this procedure was repeated until full protection from *HpaII* digestion was observed. Following digestion with *HindIII* and *EcoRV* restriction enzymes, each fragment was then ligated into a pGEM-luc vector (Promega) at the *HindIII* and *BamHI* or *XbaI* and *BamHI* sites in the 5' to 3' (sense) or 3' to 5' (antisense) orientation, respectively. The concentration of each ligation product was determined by fractionation on a 1.5% agarose gel, by comparing bands of the expected ligation product size against a standard curve of known DNA concentration (ten fivefold serial dilutions of 2 µg/µl⁻¹ micrococcal nuclease DNA) to control for possible unequal efficiency of ligation and to ensure that equal amounts of correctly ligated plasmids were used in the transfections. The ligated plasmid was directly transfected into HEK293 cells and was not subcloned to avoid loss of methyl groups from CG dinucleotides during growth in *E. coli*, which do not express CG DNA methyltransferases. For deletion constructs of the exon 1_F *NR3C1* promoter plasmids were prepared and ligations verified in the same manner as described above, except that oligonucleotides for *NR3C1* promoter amplification were designed that incorporated *HindIII* and *EcoRV* restriction sites, obviating the need for ligation into PCR2.1 vector before ligation into the pGEM-luc vector (also see **Supplementary Methods**).

For the NGFI-A plasmid, we subcloned the *EGR1* coding sequence into a TOPO-His expression vector (pEF6/V5-His TOPO TA Expression kit, Invitrogen)⁴. In co-transfection studies, human embryonic kidney HEK293 cells were plated at a density of 6×10^4 in six-well dishes and transiently co-transfected with a total amount of 1.5 µg of plasmid DNA (1.0 µg of *NR3C1* promoter ligated into the pGEM-luc plasmid and 0.5 µg of NGFI-A expression plasmid or 0.5 µg of control pEF6/V5 plasmid) using the calcium phosphate method. HEK293 cells were maintained as a monolayer in DMEM (Invitrogen) containing 10% fetal calf serum (Colorado Serum Company). The cells were harvested 72 h after transfection and lysed, and luciferase activity was assayed using the Luciferase Assay System (Promega) according to the manufacturer's protocol.

Chromatin immunoprecipitation assay for NGFI-A. We carried out chromatin immunoprecipitation assays³⁰ by postfixing cells in 37% formaldehyde and then pelleted them before lysis and sonication. We reserved one tenth of the sample as 'input' to quantify the amount of DNA before immunoprecipitation. For the remainder of each sample, extracted chromatin was immunoprecipitated using rabbit polyclonal antibody to NGFI-A (antibody) or normal rabbit IgG (nonspecific; both from Santa Cruz Biotechnology). All of the DNA was then uncrosslinked and subjected to qRT-PCR, using primers directed at the luciferase gene immediately downstream of the transfected *NR3C1* promoter (sense, 5'-AGA GAT ACG CCC TGG TTC C-3'; antisense, 5'-CCA ACA CCG GCA TAA AGA A-3'; $T_m = 54$ °C). The signal for each sample was calculated by dividing the value of the antibody by the input. Each resulting value was multiplied by a constant (1×10^6) to plot the values obtained from the experiments on logarithmic axes.

Statistical analyses. Statistical analyses were conducted using Statview or JMP 7 (SAS Institute). Data are presented as mean \pm s.e.m. For DNA methylation analysis, the percentage of methylated clones for each subject was tabulated by dividing the number of clones with at least one methylated CpG site by the total number of clones. A factorial ANOVA was used to compare the percentage of methylated clones for each subject as the dependent variable and group

(suicide abused, suicide nonabused or control) as the between groups factor. To examine differential methylation across CpG sites methylated *in vitro*, we compared the total number of methylated CpG sites across the *NR3C1* promoter ($n = 33$) for all clones per group (that is, 12 subjects \times 20 clones = 240 clones per group) using ANOVA followed by Bonferroni corrected *post hoc* comparisons. For RNA expression analysis, ANOVA followed by PLSD *post hoc* tests were used to examine differences between the suicide victim and control group. Unpaired *t* tests were used to compare groups of subjects with different clinical diagnoses (for example, subjects with mood disorders versus subjects without mood disorders). The relationships between DNA methylation, expression, age at death, PMI and brain pH were analyzed using linear regression analysis. Factorial ANOVA were used for *in vitro* analyses of *NR3C1* promoter, followed by *post hoc* analyses. Statistical significance was determined at $P \leq 0.05$ and analyses included type 1 error correction for multiple comparisons where applicable.

Note: Supplementary information is available on the Nature Neuroscience website.

ACKNOWLEDGMENTS

This research was supported by grants from the US National Institutes of Health (National Institute of Child Health and Human Development; M.J.M. and M.S.), the Canadian Institutes for Health Research (M.J.M., M.S. and G.T.), a Team Grant from the Human Frontiers Science Program (M.J.M. and M.S.) and a Maternal Adversity, Vulnerability and Neurodevelopment Project grant from the Canadian Institutes for Health Research (M.J.M. and M.S.).

Published online at <http://www.nature.com/natureneuroscience/>
Reprints and permissions information is available online at <http://npg.nature.com/reprintsandpermissions/>

1. Meaney, M.J. Maternal care, gene expression, and the transmission of individual differences in stress reactivity across generations. *Annu. Rev. Neurosci.* **24**, 1161–1192 (2001).
2. Higley, J.D., Hasert, M.F., Suomi, S.J. & Linnoila, M. Nonhuman primate model of alcohol abuse: effects of early experience, personality and stress on alcohol consumption. *Proc. Natl. Acad. Sci. USA* **88**, 7261–7265 (1991).
3. Liu, D. *et al.* Maternal care, hippocampal glucocorticoid receptors and hypothalamic-pituitary-adrenal responses to stress. *Science* **277**, 1659–1662 (1997).
4. Weaver, I.C. *et al.* Epigenetic programming by maternal behavior. *Nat. Neurosci.* **7**, 847–854 (2004).
5. de Kloet, E.R., Joels, M. & Holsboer, F. Stress and the brain: from adaptation to disease. *Nat. Rev. Neurosci.* **6**, 463–475 (2005).
6. Boyle, M.P. *et al.* Acquired deficit of forebrain glucocorticoid receptor produces depression-like changes in adrenal axis regulation and behavior. *Proc. Natl. Acad. Sci. USA* **102**, 473–478 (2005).
7. Ridder, S. *et al.* Mice with genetically altered glucocorticoid receptor expression show altered sensitivity for stress-induced depressive reactions. *J. Neurosci.* **25**, 6243–6250 (2005).
8. Reichardt, H.M., Tronche, F., Bauer, A. & Schutz, G. Molecular genetic analysis of glucocorticoid signaling using the Cre/loxP system. *Biol. Chem.* **381**, 961–964 (2000).
9. De Bellis, M.D. *et al.* Hypothalamic-pituitary-adrenal axis dysregulation in sexually abused girls. *J. Clin. Endocrinol. Metab.* **78**, 249–255 (1994).
10. Pruessner, J.C., Champagne, F., Meaney, M.J. & Dagher, A. Dopamine release in response to a psychological stress in humans and its relationship to early life maternal care: a positron emission tomography study using [¹¹C]raclopride. *J. Neurosci.* **24**, 2825–2831 (2004).
11. Heim, C. & Nemeroff, C.B. The role of childhood trauma in the neurobiology of mood and anxiety disorders: preclinical and clinical studies. *Biol. Psychiatry* **49**, 1023–1039 (2001).
12. Webster, M.J., Knable, M.B., O'Grady, J., Orthmann, J. & Weickert, C.S. Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders. *Mol. Psychiatry* **7**, 985–994 (2002).
13. Schatzberg, A.F., Rothschild, A.J., Langlais, P.J., Bird, E.D. & Cole, J.O. A corticosteroid/dopamine hypothesis for psychotic depression and related states. *J. Psychiatr. Res.* **19**, 57–64 (1985).
14. Isometsa, E.T. *et al.* Suicide in major depression. *Am. J. Psychiatry* **151**, 530–536 (1994).
15. Widom, C.S., DuMont, K. & Czaja, S.J. A prospective investigation of major depressive disorder and comorbidity in abused and neglected children grown up. *Arch. Gen. Psychiatry* **64**, 49–56 (2007).
16. Fergusson, D.M., Horwood, L.J. & Lynskey, M.T. Childhood sexual abuse and psychiatric disorder in young adulthood. II. Psychiatric outcomes of childhood sexual abuse. *J. Am. Acad. Child Adolesc. Psychiatry* **35**, 1365–1374 (1996).
17. Weaver, I.C. *et al.* The transcription factor nerve growth factor-inducible protein a mediates epigenetic programming: altering epigenetic marks by immediate-early genes. *J. Neurosci.* **27**, 1756–1768 (2007).

18. McCormick, J.A. *et al.* 5'-heterogeneity of glucocorticoid receptor messenger RNA is tissue specific: differential regulation of variant transcripts by early-life events. *Mol. Endocrinol.* **14**, 506–517 (2000).
19. Turner, J.D. & Muller, C.P. Structure of the glucocorticoid receptor (*NR3C1*) gene 5' untranslated region: identification and tissue distribution of multiple new human exon 1. *J. Mol. Endocrinol.* **35**, 283–292 (2005).
20. Breslin, M.B., Geng, C.D. & Vedeckis, W.V. Multiple promoters exist in the human *GR* gene, one of which is activated by glucocorticoids. *Mol. Endocrinol.* **15**, 1381–1395 (2001).
21. Encio, I.J. & Detera-Wadleigh, S.D. The genomic structure of the human glucocorticoid receptor. *J. Biol. Chem.* **266**, 7182–7188 (1991).
22. Weaver, I.C. *et al.* Reversal of maternal programming of stress responses in adult offspring through methyl supplementation: altering epigenetic marking later in life. *J. Neurosci.* **25**, 11045–11054 (2005).
23. Razin, A. CpG methylation, chromatin structure and gene silencing a three-way connection. *EMBO J.* **17**, 4905–4908 (1998).
24. Bird, A. Molecular biology. Methylation talk between histones and DNA. *Science* **294**, 2113–2115 (2001).
25. Clark, S.J., Harrison, J., Paul, C.L. & Frommer, M. High sensitivity mapping of methylated cytosines. *Nucleic Acids Res.* **22**, 2990–2997 (1994).
26. Yamada, K. *et al.* Genetic analysis of the calcineurin pathway identifies members of the EGR gene family, specifically EGR3, as potential susceptibility candidates in schizophrenia. *Proc. Natl. Acad. Sci. USA* **104**, 2815–2820 (2007).
27. Cervoni, N. & Szyf, M. Demethylase activity is directed by histone acetylation. *J. Biol. Chem.* **276**, 40778–40787 (2001).
28. Crosby, S.D., Puetz, J.J., Simburger, K.S., Fahrner, T.J. & Milbrandt, J. The early response gene NGFI-C encodes a zinc finger transcriptional activator and is a member of the GCGGGGCG (GSG) element-binding protein family. *Mol. Cell. Biol.* **11**, 3835–3841 (1991).
29. Plotsky, P.M. *et al.* Long-term consequences of neonatal rearing on central corticotropin-releasing factor systems in adult male rat offspring. *Neuropsychopharmacology* **30**, 2192–2204 (2005).
30. Oberlander, T.F. *et al.* Prenatal exposure to maternal depression, neonatal methylation of human glucocorticoid receptor gene (*NR3C1*) and infant cortisol stress responses. *Epigenetics* **3**, 97–106 (2008).
31. Fleming, A.S., O'Day, D.H. & Kraemer, G.W. Neurobiology of mother-infant interactions: experience and central nervous system plasticity across development and generations. *Neurosci. Biobehav. Rev.* **23**, 673–685 (1999).
32. Pilowsky, D.J. *et al.* Children of depressed mothers 1 year after the initiation of maternal treatment: findings from the STAR*D child study. *Am. J. Psychiatry* **165**, 1136–1147 (2008).
33. Holsboer, F. The corticosteroid receptor hypothesis of depression. *Neuropsychopharmacology* **23**, 477–501 (2000).
34. Neigh, G.N. & Nemeroff, C.B. Reduced glucocorticoid receptors: consequence or cause of depression? *Trends Endocrinol. Metab.* **17**, 124–125 (2006).
35. Abdolmaleky, H.M. *et al.* Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. *Hum. Mol. Genet.* **15**, 3132–3145 (2006).
36. Grayson, D.R. *et al.* Reelin promoter hypermethylation in schizophrenia. *Proc. Natl. Acad. Sci. USA* **102**, 9341–9346 (2005).
37. Siegmund, K.D. *et al.* DNA methylation in the human cerebral cortex is dynamically regulated throughout the life span and involves differentiated neurons. *PLoS ONE* **2**, e895 (2007).
38. Ernst, C. *et al.* The effects of pH on DNA methylation state: *in vitro* and postmortem brain studies. *J. Neurosci. Methods* **174**, 123–125 (2008).
39. Vythilingam, M. *et al.* Childhood trauma associated with smaller hippocampal volume in women with major depression. *Am. J. Psychiatry* **159**, 2072–2080 (2002).
40. Seguin, M. *et al.* Life trajectories and burden of adversity: mapping the developmental profiles of suicide mortality. *Psychol. Med.* **37**, 1575–1583 (2007).
41. Brezo, J. *et al.* Natural history of suicidal behaviors in a population-based sample of young adults. *Psychol. Med.* **37**, 1563–1574 (2007).
42. Kaufman, J., Plotsky, P.M., Nemeroff, C.B. & Charney, D.S. Effects of early adverse experiences on brain structure and function: clinical implications. *Biol. Psychiatry* **48**, 778–790 (2000).
43. Teicher, M.H., Andersen, S.L., Polcari, A., Anderson, C.M. & Navalta, C.P. Developmental neurobiology of childhood stress and trauma. *Psychiatr. Clin. North Am.* **25**, 397–426 (2002).
44. Fisher, P.A., Gunnar, M.R., Chamberlain, P. & Reid, J.B. Preventive intervention for maltreated preschool children: impact on children's behavior, neuroendocrine activity and foster parent functioning. *J. Am. Acad. Child Adolesc. Psychiatry* **39**, 1356–1364 (2000).
45. Brezo, J. *et al.* Predicting suicide attempts in young adults with histories of childhood abuse. *Br. J. Psychiatry* **193**, 134–139 (2008).
46. Sequeira, A. & Turecki, G. Genome wide gene expression studies in mood disorders. *OMICS* **10**, 444–454 (2006).
47. Spitzer, R.L., Williams, J.B., Gibbon, M. & First, M.B. The Structured Clinical Interview for DSM-III-R (SCID). I: history, rationale and description. *Arch. Gen. Psychiatry* **49**, 624–629 (1992).
48. Dumais, A. *et al.* Risk factors for suicide completion in major depression: a case-control study of impulsive and aggressive behaviors in men. *Am. J. Psychiatry* **162**, 2116–2124 (2005).
49. Bifulco, A., Brown, G.W. & Harris, T.O. Childhood Experience of Care and Abuse (CECA): a retrospective interview measure. *J. Child Psychol. Psychiatry* **35**, 1419–1435 (1994).
50. Frommer, M. *et al.* A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. *Proc. Natl. Acad. Sci. USA* **89**, 1827–1831 (1992).